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Abstract: In the current era of high-throughput drug discovery and development, 
molecular modeling has become an indispensable tool for identifying, optimizing and 
prioritizing small-molecule drug candidates. The required background in computational 
chemistry and the knowledge of how to handle the complex underlying protocols, 
however, might keep medicinal chemists from routinely using in silico technologies. Our 
objective is to encourage those researchers to exploit existing modeling technologies more 
frequently through easy-to-use graphical user interfaces. In this account, we present two 
innovative tools (which we are prepared to share with academic institutions) facilitating 
computational tasks commonly utilized in drug discovery and development: (1) the 
VirtualDesignLab estimates the binding affinity of small molecules by simulating and 
quantifying their binding to the three-dimensional structure of a target protein; and (2) the 
MD Client launches molecular dynamics simulations aimed at exploring the  
time-dependent stability of ligand–protein complexes and provides residue-based 
interaction energies. This allows medicinal chemists to identify sites of potential 
improvement in their candidate molecule. As a case study, we present the application of 
our tools towards the design of novel antagonists for the FimH adhesin. 
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1. Introduction 
Molecular modeling has become an integral part of drug discovery and development, with 
numerous documented examples of successful employment of computational approaches to answer 
key questions in the field of molecular design. For instance, structure-based design techniques, 
including small-molecule docking and scoring, can provide structural and energetic information on  
ligand–protein binding and, hence, guide the design of more potent candidate molecules [1,2]. 
Additionally, quantitative structure-activity relationships (QSAR) models can provide reliable 
estimates of binding affinities, particularly of hypothetical ligands—prior to their laborious and costly 
synthesis and biological testing [3,4]. Molecular dynamics (MD) simulations address more challenging 
questions regarding the dynamic nature of ligand–receptor interactions [5–11]. Overall, virtual 
screening can increase the efficiency and reduce time and cost of lead identification [12,13]. A number 
of commercially available software packages handle one or more of these tasks, e.g., the Schrödinger 
Suite [14], the Accelrys Discovery Studio [15], the SYBYL-X Suite [16] or the Molecular Operating 
Environment [17]. Furthermore, a wealth of modeling tools are available free-of-charge, including 
AutoDock for automated docking [18], QuasarX for multi-dimensional QSAR [19], Desmond for 
molecular dynamics simulations [20] and DOCK Blaster for virtual screening [21]. 
Medicinal chemists involved in design of new ligands for some macromolecular target are 
nowadays knowledgeable of the binding site’s topology at the molecular level. This degree of 
familiarity with the target provides valuable guidance for modeling techniques, such as docking 
proposed ligands to that target or developing a QSAR for predicting binding affinities. Such optimized 
modeling methodologies could, in turn, guide the medicinal chemists’ decision making. However, 
making the best use of these and other modeling techniques requires a tedious and repetitive process of 
setting and calibrating parameters, as well as collecting and organizing the results. Designing an 
intuitive interface that encapsulates and hides the complexity of the underlying technologies from the 
end-user would, thus, motivate medicinal chemists to use modeling tools more frequently. 
In this article, we present two novel platforms addressing commonly required tasks in modern drug 
design workflow: the VirtualDesignLab for predicting binding mode and affinity and the MD Client 
for investigating interaction dynamics of ligand–protein complexes (Figure 1). We discuss the 
development of the underlying models and technologies used in both tools and demonstrate their 
recent employment in our lab for the design and optimization of novel antagonists for FimH [22–24], a 
bacterial lectin playing a crucial role in the initial stages of urinary tract infections. Since the goal of 
the present work is to develop versatile tools that can be easily tuned for any structure-based drug 
design project, we will conclude with reviewing the steps required to apply/extend our tools for use 
with other protein targets. 
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Figure 1. Tools presented in this article handle two common tasks in modern  
computer-aided drug design workflow. The VirtualDesignLab predicts binding mode and 
estimates the associated binding affinity of prospective ligands. The MD Client facilitates 
simulation and analysis of the dynamics in ligand–protein complexes. In concert with other 
software predicting pharmacokinetic (e.g., QikProp [25]) and toxicological profiles  
(e.g., the VirtualToxLab [26]), our tools equip medicinal chemists with a multi-purpose 
molecular-modeling kit. 
 
2. Methods 
2.1. VirtualDesignLab 
The VirtualDesignLab is an in silico tool developed at our institute (based on the VirtualToxLab 
framework [26] shared by the Biographics Laboratory 3R) simulating and quantifying the binding of 
small molecules to a macromolecular target. The technology employs automated, flexible docking 
combined with multi-dimensional quantitative structure-activity relationships (mQSAR). Controlled 
by an easy-to-use interface, the VirtualDesignLab allows medicinal chemists to perform quick and 
straightforward design, screening and structural inspection of any compound of interest [27]. 
In order to provide a reliable in silico affinity estimate for a given system, it is necessary to account 
for protein-ligand interactions, solvation and entropic phenomena. In our example system, FimH 
adhesin, we utilized a set of 108 compounds, along with their experimental affinity data, to develop 
and validate a corresponding mQSAR model (Table 1). When generating the model, the initial 
compound structures were constructed using the integrated model-building tool and then optimized 
with MacroModel [28]. Atomic partial charges were computed using the AMSOL package [29]. All 
structures were subjected to the conformational-searching algorithm ConfGen [30], resulting in sets of 
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low-energy conformations for each molecule in aqueous solution. Energetically feasible binding 
conformations (within 10 kcal/mol from the lowest-energy structure) were identified by means of 
automated docking to two three-dimensional structures (“in” and “out” state, cf. below) of the FimH 
carbohydrate-binding domain. The employed alignment (Alignator) [31] and docking (Cheetah) [32] 
protocols allowed for flexibility of both ligand and the protein (induced fit), as well as dynamic 
solvation. Several templates (based on experimental structures) were used for the pre-alignment in 
order to account for distinct modes of binding to FimH (referred to as “in” and “out”) reported 
previously [23,33]. The underlying protein structures were retrieved from the Protein Data Bank (PDB 
codes 1UWF and 3MCY available at 1.69 Å and 2.90 Å resolution, respectively) and pre-processed 
(calculation of hydrogen-atom positions, hydrogen-bond network optimization, energy minimization) 
with the Protein Preparation Wizard in Maestro [34]. A total of 282 docking poses (allowing for 
multiple poses per ligand) comprising a 4D data set were then used as input (84 training and 24 test 
substances) for the mQSAR software Quasar [35] to generate a series of quasi-atomistic binding-site 
models. The underlying model families (comprising 200 members) were evaluated in  
consensus-scoring mode—along with a direct force-field scoring in Cheetah [32] and the comparison 
of a molecule’s interaction energy in a box of pre-equilibrated water and in the binding site. For 
validation, we additionally employed an alternative receptor-modeling concept, Raptor [28], featuring 
a substantially different scoring function. 
Table 1. Structures and binding affinities (pIC50: negative logarithm of IC50 [M]) for  
52 compounds employed to develop the QSAR model. The remaining data cannot be 
disclosed at this time, due to pending patent applications. 
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Table 1. Cont. 
 R Exp. affinity 
Pred. 
affinity Residual  R 
Exp. 
affinity 
Pred. 
affinity Residual 
21 
 
6.9 7.1 0.2 22 6.4 7.1 0.7 
23 
 
6.3 7.1 0.8 24 6.3 7.0 0.7 
25  6.8 7.4 0.6 26 6.5 6.7 0.2 
27  7.2 6.8 −0.4 28 8.6 8.0 −0.6 
29  6.1 6.8 0.7 30 6.6 7.3 0.7 
31 
 
6.8 6.8 0 32 7.0 7.2 0.2 
33 
 
6.7 6.9 0.2 34 6.8 6.8 0 
35 
 
6.7 6.7 0 36 6.5 6.3 −0.2 
37 
 
6.6 6.8 0.2 38 6.6 6.6 0 
39 
 
6.8 7.3 0.5 40 6.7 6.5 −0.2 
41  6.3 6.5 0.2 42 8.0 7.7 −0.3 
43 
 
8.2 7.5 −0.7 44 7.7 7.6 −0.1 
45 
 
7.6 7.5 −0.1 46 8.3 7.8 −0.5 
47 
 
7.7 7.4 −0.3 48 7.4 7.3 −0.1 
49 
 
7.5 7.3 −0.2 50 7.8 7.4 −0.4 
51 
 
8.3 7.9 −0.4 52 8.0 7.4 −0.6 
Every compound submitted to the VirtualDesignLab server (by means of imported PDB files or the 
integrated model builder) is subjected to identical protocols as those employed to train and validate the 
underlying mQSAR model(s) (Figure 2). The affinity is calculated based on multiple components of 
the binding energy (Figure 3). Protein–ligand interaction and internal strain energies (Cheetah and 
Quasar) are obtained using a directional force field with polarization terms [36]. The desolvation costs 
are calculated for the global minimum obtained from the conformational search, using a continuum 
solvation model. Loss of entropy is approximated from the number of rotatable bonds constrained 
upon binding to the protein. Induced-fit energy calculation is an inherent function of the Quasar 
algorithm. The affinity predictions are based on (up to) eight docking poses as obtained from 
Alignator/Cheetah (4D) and take into account (up to) six induced-fit mechanisms (5D) and two 
solvation (6D) scenarios in order to account for the unique properties of certain binding sites (e.g., the 
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and/or downloaded (in PDB format) upon job completion. The latter files also serve as input for other 
software, including the MD Client. 
Figure 2. VirtualDesignLab flowchart (left) and an example of a typical workflow based 
on the FimH receptor (right). The compound of interest is designed using the built-in 3D 
model builder or imported from an external file. The main step involves the conformational 
sampling of the ligand in the protein’s binding pocket, where all feasible poses are retained 
and used as input for the subsequent mQSAR. Structure management options and job 
controls are all accessible from a central interface window. References to the individual 
pieces of software are given in text. 
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Figure 3. The equation for calculating the binding energy used in the 
VirtualDesignLab/VirtualToxLab and the directional force field employed in Cheetah and 
Quasar [32]. The individual terms—quantifying experimentally accessible quantities, such 
as bond lengths, bond angles, torsion angles, van der Waals contacts, geometries of 
hydrogen bonds, electrostatic and metal-ligand interactions, as well as ligand→protein 
polarization—are described in greater detail in the software documentation found at 
http://www.biograf.ch/index.php?id=software. 
 
2.2. MD Client 
In addition to binding affinities estimated from mQSAR based on the docking simulations, 
medicinal chemists might wish to analyze the kinetic stability of ligand–protein interaction used by 
means of molecular-dynamics (MD) simulations. MD has been successful in studying structural 
fluctuations in proteins [37–39], lipids [40–42] and nucleic acids [43,44], as well as in the refinement 
of structures solved by X-ray crystallography and NMR [5]. Despite the availability of a wealth of 
software packages for performing MD simulations, (e.g., Desmond [20], Amber [45], CHARMM [46], 
GROMOS [47] and GROMACS [48]), the lengthy setup and laborious post-processing act as a barrier, 
preventing users from routinely utilizing these simulations. We therefore developed the MD Client to 
overcome this limitation by requiring as few settings as possible to quickly and reliably highlight basic 
features of the dynamics of the studied protein–ligand complex. Our MD Client is designed specifically 
for use by bench medicinal chemists interested in exploring ligand–protein interaction dynamics. 
2.2.1. The MD Client Interface 
The MD Client utilizes a simple and intuitive GUI front-end and a more sophisticated back-end that 
handles all “under-the-hood” tasks, from cleaning the input structure to post-processing MD trajectory 
and gathering energy results. Both front- and back-end programs were developed in python 2.6 
(http://www.python.org) using standard extensions, such as the TkInter GUI package and the 
matplotlib library for rendering interactive 2D plots. The front-end has been compiled for Mac OS X, 
Linux and Windows operating systems. The communication between the front-end and the back-end 
on the remote server is carried out via a Secure Shell (SSH) protocol. A molecular dynamics 
simulation of a ligand–protein complex (as obtained, for instance, from the VirtualDesignLab) is 
launched by a single-click in the MD Client interface. The MD Client provides control over the basic 
parameters of submitted MD simulation: namely its length and frequency of taking snapshots for 
subsequent energy analysis and movie production (Figure 4). The “Advanced Options”, button enables 
the user to control more details of the MD simulation; yet the default options are adequate in most 
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cases. A list box keeps track of jobs currently on the server and their current status. The user can 
monitor the progress of running jobs or, when needed, terminate them at any stage. 
Figure 4. Appearance of the user interface of MD Client; top-left: list of jobs currently on 
remote server; bottom: basic simulation settings; and right: results download and analysis. 
 
MD simulations require different types of data input. The most important is the structure file 
containing input geometries of the ligand–protein complex. Currently, the MD Client accepts files with 
Protein Data Bank (PDB) format [49]. The VirtualDesignLab output structures (i.e., ligand-protein 
complexes) can be directly used as input for the MD Client. When an MD simulation is completed, the 
user can download extracted frames as standard PDB files for viewing. For the 3D visualization of 
structures, several free 3D-rendering tools, such as Visual Molecular Dynamics (VMD) [50], are 
available. To facilitate the importing of MD trajectories into VMD, we added a functionality that 
automatically generates a VMD visualization-state file linked to the downloaded frames. The user can 
choose between different pre-defined visualization styles and simply click on “Generate VMD Movie” 
in the MD Client interface (Figure 4) to produce a file that can be loaded directly into VMD. This 
spares the user the time and effort needed to load individual PDB files and set up the view options in 
VMD. Most importantly, the user can use MD Client’s built-in plotting tool to analyze ligand–protein 
interaction dynamics (cf. Figure 7) and compare them amongst multiple systems, which we are going 
to demonstrate in the results section on selected antagonists binding to the FimH receptor. 
2.2.2. The MD Client Back-end 
The MD Client back-end resides on the remote server, where all computational jobs are to take 
place. It utilizes Schrödinger’s Python API (http://www.schrodinger.com/pythonapi) for reading 
structures, launching MD simulations and computing per-residue interaction energies. It receives input 
structure and primary simulation settings from the front-end. Figure 5 shows how the MD Client  
back-end processes input structures into useful quantities. It starts by constructing atom connectivity 
and bond orders for the submitted structure and doing a short energy minimization to relieve structural 
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inconsistencies in bond lengths, angles, steric clashes, etc. The MD Client back-end automatically 
identifies the ligand-like molecule and defines binding site residues as all residues within 8 Å (default) 
from ligand atoms. This definition is employed for subsequent use in energy computations and  
movie production. 
Figure 5. Workflow of the MD Client and communication between front-end and  
back-end. 
 
The MD Client back-end employs the Desmond package from the D. E. Shaw Research laboratory 
to perform the MD simulations [51,52]. Desmond and its source code are distributed under free license 
to non-commercial and academic users. It uses novel parallel algorithms and numerical techniques to 
achieve high performance and accuracy on platforms containing a large number of processors, but may 
also be executed on a single-processor computer [20]. Desmond’s System Builder soaks the submitted 
ligand–protein complex into a TIP3P water box extending 10 Å beyond any of the complex’s atoms. It 
adds counter ions to neutralize the simulation box and 0.15 M sodium and chloride ions to 
approximate physiological conditions. The complex is first minimized to a convergence gradient 
threshold of 1.0 kcal/(mol·Å). The molecular-dynamics protocol utilizes the OPLS2005 force field and 
the NPT ensemble (constant number of particles, pressure and temperature) at 300 K, with periodic 
boundary conditions. The production run of the user-defined length is preceded by 24 ps of the 
Desmond default relaxation protocol. After completion of the MD simulation, the MD Client back-end 
extracts frames at the user-defined intervals and saves them as standard PDB files. The user can 
download these frames for later viewing and analysis. Finally, the extracted frames are analyzed using 
the component-interactions script in Maestro [34] to compute interaction energies between the ligand 
and individual amino acids defining the binding site along the MD simulations. Ligand-residue 
interaction energies are calculated as the sum of the (OPLS2005) van der Waals and electrostatic 
terms. This dynamic-interaction profile is saved as a time series in a comma-separated-values (csv) file 
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for subsequent download by the user or for interactive plotting and analysis using the MD Client  
front-end interface. 
3. Results and Discussion 
3.1. VirtualDesignLab 
The current FimH Quasar model for the VirtualDesignLab was established based on structural and 
biological data of 108 mannose-based inhibitors (with IC50 values ranging from 220 μM to 2.4 nM) 
displaying diverse PK/PD profiles. Compound synthesis, biological assays [53] and model 
development were performed in-house, ensuring consistency of all results. Table 1 shows the 
structures, experimental and predicted affinities of compounds used for developing the model. The 
QSAR model based on a genetic algorithm converged at a cross-validated r2 of 0.805 and yielded a 
predictive r2 of 0.596 (Figure 6a). The only modest value of the predictive r2 is a consequence of the 
relatively narrow range of test compound affinities (as some substances were necessary for the training 
set due to their structural uniqueness). The performance of the model is therefore better reflected by 
the individual predictions (23 out of 24 test substances within a factor of 10 from their experimental 
affinity). We further challenged the FimH model by using Y-scrambling and consensus scoring with 
the software Raptor (dual-shell 5D-QSAR; Figures 6b and S1) [54]. All tests, including the  
processing of additional external compounds, confirmed the predictive power of the mQSAR  
model-based framework. 
Figure 6. Comparison between experimental (horizontal axis) and predicted pK values 
(vertical axis) for (a) the Quasar model and (b) the Raptor model. Black and red points 
represent compounds of the training and test set, respectively. Vertical bars indicate the 
estimated standard deviations of the prediction. Dashed lines are drawn at factors of 10 
from the experimental value. 
 
The VirtualDesignLab is aimed at predicting the binding affinity for a given compound within a 
factor of 10 from the experimental value. Currently, the affinity prediction for a single compound 
requires approximately one hour of CPU time—a good balance between accuracy and processing time. 
Special treatment may, however, be required for compounds retaining flexibility upon binding. In such 
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cases, improved entropy estimation (a method is currently in development at our institute) or a  
non-static approach, such as the one offered by the MD Client (cf. below), may be necessary. We 
would like to emphasize that the framework is independent of the FimH mQSAR model (presented 
here), as it only requires the generation and validation of a new QSAR model for any target protein of 
interest. This can be developed using by freely available software, e.g., Quasar [35]. 
3.2. MD Client 
In the MD Client, the outcome of an MD simulation includes a set of frames extracted from the MD 
trajectory and a dynamic-interaction profile comprising per-residue interaction energies between 
ligand and protein for all time points. An interactive plot of computed interaction profiles is readily 
accessible from the MD Client interface (Figure 7). The plot created by the matplotlib python 
extension is cumulative, i.e., it can incorporate dynamic profiles from several simulations in the same 
plot with automated coloring and legend generation. Comparing dynamic profiles of different 
simulations may provide valuable clues, for instance, about interaction modes of different ligands 
and/or key residues in ligand recognition and binding. We chose five structurally distinct FimH ligands 
(9, 17, 18, 28 and 37) to demonstrate the usefulness of dynamic-interaction profiles. Examination of 
their dynamic interaction energies with two key FimH residues (Gln133 and Phe1) indicates that these 
interactions are maintained throughout the entire simulation and that they don’t significantly differ 
among different ligand classes (Figure 7a,b). These residues are typically involved in an extended 
hydrogen-bond network with the mannose moiety common to FimH binders. The profiles also show 
that the interaction with the N-terminal NH3+ moiety of Phe1 results in a considerably larger 
contribution to the binding enthalpy compared to Gln133. Automated docking of FimH ligands 
typically predicts a hydrogen bond from the 3-OH of the mannose moiety to the Asp140 residue to be 
thermodynamically favorable. Interestingly, this hydrogen bond does not seem to be kinetically stable, 
since it is broken within the first 0.5 ns and is never re-established throughout the entire simulation as 
can be observed in the profiles of all studied compounds (Figure 7c). 
Figure 7. Dynamic per-residue interaction plots for five FimH ligands generated by the 
interactive plotting feature of MD Client; (a) Gln133, (b) Phe1, (c) Asp140 and (d) Tyr48. 
Vertical axis: protein–ligand interaction energies (kcal/mol); horizontal axis: molecular 
dynamics simulation time (ns). The colors mark the individual compounds shown above. 
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Figure 7. Cont. 
 
The various classes of FimH ligands differ in their interaction patterns with the so-called tyrosine 
gate lined by Tyr48 and Tyr137 located at the entrance to the mannose-binding site (Figure 8) [23]. 
The interaction dynamics show that compound 28 exhibits the strongest interaction with Tyr48, which 
could be explained by its unique scaffold that allows a preferred interaction with the tyrosine side 
chain (Figure 7d). Compounds 9 and 18 display a favorable interaction with Tyr48, yet of lower 
magnitude than 28, which explains the superior affinity of the latter (see Table 1). Finally, two ligands 
seem to lack this favorable interaction with Tyr48; namely 17 and 37, which also coincides with their 
relatively lower affinities. This could be rationalized by the lack of a side chain capable of interacting 
with the Tyr48 in 17 and the inherent rigidity of 37 due to a lack of glycosidic oxygen in the linker 
between mannose and the aromatic aglycone. 
Figure 8. Illustration of (a) in binding mode of 18 and (b) out binding mode of 28, within 
the tyrosine gate of FimH binding site. References to different binding modes of FimH 
ligands are given in the methods section. 
 
Int. J. Mol. Sci. 2013, 14 696 
 
4. Software Extension/Repurposing 
The philosophy behind all our software is to allow for extendibility, as well as redirection,  
towards different targets of interest. In the following, we provide a brief overview of the  
corresponding requirements. 
4.1. VirtualDesignLab 
Assuming that a decent number of ligands with experimental affinity data are available for the 
given target, a three-dimensional protein-ligand structure that will serve for automated, flexible 
docking is required. These are usually obtained by means of crystallography or homology modeling 
and must typically be further refined (addition of hydrogen atoms, completion of missing amino-acid 
residues or their side chains, completion/generation of the solvent shell, energy minimization). These 
tasks can be accomplished through numerous, freely accessible computational tools. With the structure 
at hand, potential binding poses of all tested compounds need to be obtained. For this step, any  
flexible-docking software may be employed, including Alignator/Cheetah discussed in this article. The 
ensemble of potential binding modes can be compiled into a 4D data set to serve as input for the 
generation of the binding site surrogate. Though this task is best handled using the Quasar software, a 
QSAR model of different origin could also potentially be utilized. It should be noted, however, that 
even though structure preparation and pose generation are relatively simple tasks requiring no more 
than a few days of work, developing and validating a robust and reliable QSAR model is a complex 
and lengthy procedure. Also, given the vast diversity of the computational methods, personal 
communication with the authors of this article would likely be necessary in order to integrate a QSAR 
model with the VirtualDesignLab framework. 
4.2. MD Client 
The MD Client relies on the Desmond package at its back-end terminal to perform MD simulations. 
Desmond can be obtained free of charge for academics and non-commercial users. Once a working 
Desmond installation is available, the user needs to point the MD Client to where the back-end is 
located by providing the necessary SSH credentials. The MD Client can basically take it from there, 
since it has internal routines for identifying protein and ligand, job submission and monitoring, as well 
as calculating, organizing and plotting the interaction energy results. 
5. Conclusions 
Over the past three decades, much progress has been made in developing and validating innovative 
computational algorithms for common drug design-related tasks. In their perspective on the future of 
medicinal chemistry, Satyanarayanajois and Hill [55] stated that emerging medicinal chemists should 
additionally acquire “computational and cheminformatics acumen considerably greater than in years 
past”. In a related analysis, Ritchie and McLay [56] concluded that the goal of encouraging medicinal 
chemists to rely more on computational chemistry tools could be best achieved via specially designed 
tools that are “well-thought-out, suitable for their needs, able to generate useful, timely and valid 
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results”. Similarly, we trust that adopting this strategy will ultimately maximize the benefit of  
state-of-the-art modeling technologies in the field of drug design and development. 
To this end, we designed versatile single-click tools to assist medicinal chemists in performing two 
routine modeling tasks: the VirtualDesignLab for predicting binding mode and affinity of potential 
drug candidates and the MD Client for investigating dynamic behavior and energetics of ligand-protein 
complexes. Thanks to their modular design based mainly on self-developed algorithms, our tools allow 
easy modification, extension, as well as reorientation towards other targets and platforms of interest. 
Our group previously introduced the OpenVirtualToxLab for prediction of the toxic potential of drug 
candidates and made it freely available to academic organizations [57]. The two new tools introduced 
in this article, VirtualDesignLab and MD Client, can also be made available on request. Our future 
plans for MD Client include adding support for more molecular dynamics packages, as well as more 
analysis functionalities (for instance, surface area and entropy computations) to give more insight into 
ligand–protein interaction processes. 
In closing, we wish to emphasize that our tools are not intended to, neither can they, replace the 
expert molecular modeler. In fact, their main purpose is to facilitate handling routine drug-design 
related tasks, thus leaving the more time-consuming detailed investigation only for interesting cases. 
Our vision is to place our interfacing technologies right on the medicinal chemists’ workbench and 
keep all the complicated ‘machinery’ on a transparently maintained server. However, the simplicity of 
such tools, although tempting, should never cloud the medicinal chemists’ judgment. On the contrary, 
medicinal chemists should always employ their expertise to question the results obtained from  
such tools. 
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